Cytomx Therapeutics, Inc. (CTMX) fundamentals score
Cytomx Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 2.6 out of 10, Unhealthy fundamentals
- Growth: 2.2/10
- Profitability: 1.0/10
- Financial health: 5.4/10
- Earnings quality: 3.5/10
- Valuation: 1.4/10
Scores are calculated from Cytomx Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10